Dermatologicals
Refine Search
Pharmaceutical
Almirall and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, have entered into a research, collaboration and sublicense agreement. 19 May 2016
Pharmaceutical
Pfizer said today that it plans to acquire Anacor Pharmaceuticals for $99.25 per Anacor share. 16 May 2016
Generics
Mylan is to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings. 14 May 2016
Pharmaceutical
US drug major Eli Lilly’s Taltz for plaque psoriasis is set to achieve blockbuster status by 2022, an analyst has predicted. 11 May 2016
Pharmaceutical
Almirall this morning released financials for the first quarter of 2016, showing that total revenues were down 7.5% at 201 million euros compared with the like 2015 period. 9 May 2016
Biotechnology
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended US pharma major AbbVie’ Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS). 6 May 2016
Biotechnology
Stephen O’Hara is chief executive of OptiBiotix Health, a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strain, a statin-free cholesterol pill. He spoke to the Pharma Letter... 4 May 2016
Biotechnology
US pharma major Eli Lilly announced on Tuesday that the European Commission has granted marketing authorization for Taltz (ixekizumab) for plaque psoriasis. 26 April 2016
Pharmaceutical
Allergan says it has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. 22 April 2016
Biosimilars
Improvements in drugs will prompt the psoriasis market to rise from $6.6 billion in 2014 to more than $13.3 billion by 2024, according to research from GlobalData. 16 April 2016
Biotechnology
US company Diplomat Pharmacy has been selected by pharma major Eli Lilly to distribute Taltz (ixekizumab) for the treatment of adults with moderate-to-severe plaque psoriasis. 5 April 2016
Biotechnology
French pharma giant Sanofi and the US’s Regeneron Pharmaceuticals have announced positive results for two Phase III studies of dupilumab in patients with moderate-to-severe atopic dermatitis (AD) patients. 1 April 2016
Pharmaceutical
Irish company Fastnet Equity, which last year announced a switch of focus from oil exploration to pharmaceuticals, is seeking to complete a £29.6 million takeover of orphan drug development firm Amryt Pharmaceuticals. 31 March 2016
Pharmaceutical
US biopharma company XenoPort has entered into a license agreement under which Indian drug major Dr Reddy’s Laboratories will be granted exclusive US rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. 29 March 2016
Pharmaceutical
Chugai Pharmaceutical said on Friday that it has won a lawsuit against companies who by the decision must now stop manufacturing and marketing their generic drugs in infringement of the process patent (Patent No 3310301) on Oxarol (maxacalcitol) Ointment. 26 March 2016
Biotechnology
The US Food and Drug Administration (FDA) has approved Eli Lilly’s monoclonal antibody Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis, it has been announced. 23 March 2016
Pharmaceutical
Danish company LEO Pharma has received scientific approval for its psoriasis treatment Enstilar in the European Union (EU). 21 March 2016
Pharmaceutical
US drug developer Vitae has seen its share price soar after reporting successful results from its experimental psoriasis drug trial. 18 March 2016
Biosimilars
Commenting on the news last week of the $595 million upfront deal between AbbVie and Boehringer Ingelheim, giving rights to AbbVie to develop a psoriasis drug candidate, Bloomberg points out the treatment is aimed at entering a crowded field that includes Humira, AbbVie’s top product with $14 billion in fiscal 2015 sales. 13 March 2016
Biotechnology
AbbVie and Boehringer Ingelheim have signed a global collaboration to develop and commercialize BI 655066, an anti-interleukin (IL)-23 monoclonal biologic antibody in Phase III development for psoriasis. 7 March 2016
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze